IKKα negatively regulates ASC-dependent inflammasome activation. by Martin, Bradley N et al.
UC San Diego
UC San Diego Previously Published Works
Title
IKKα negatively regulates ASC-dependent inflammasome activation.
Permalink
https://escholarship.org/uc/item/48w3n4fp
Journal
Nature communications, 5(1)
ISSN
2041-1723
Authors
Martin, Bradley N
Wang, Chenhui
Willette-Brown, Jami
et al.
Publication Date
2014-09-30
DOI
10.1038/ncomms5977
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
IKKα negatively regulates ASC-dependent inflammasome 
activation
Bradley N. Martin1,11,12, Chenhui Wang1,12, Jami Willette-Brown2, Tomasz Herjan1, 
Muhammet F. Gulen1, Hao Zhou1, Katarzyna Bulek1, Luigi Franchi3, Takashi Sato4, 
Goutham Narla5, Xiao-Ping Zhong6, James Thomas7, Dennis Klinman4, Katherine A. 
Fitzgerald8, Michael Karin9, Gabriel Nuñez3, George Dubyak10, Yinling Hu2, and Xiaoxia Li1
1Department of Immunology, Lerner Research Institute, Cleveland Clinic Foundation, Cleveland, 
OH 44195, USA
2Cancer and Inflammation Program, Center for Cancer Research, National Cancer Institute, 
Frederick, MD 21702, USA
3Department of Pathology, University of Michigan Medical School, Ann Arbor, MI 48109; and 
Comprehensive Cancer Center, University of Michigan Medical School, Ann Arbor, MI 48109, 
USA
4Laboratory of Experimental Immunology, National Cancer Institute, Frederick, MD 21702, USA
5Institute for Transformative Molecular Medicine, Department of Medicine, Case Western 
Reserve University, Cleveland, OH 44106, USA
6Departments of Pediatrics and Immunology, Duke University Medical Center, Durham, NC 
27710, USA
7Department of Pediatric Medicine, Baylor College of Medicine, Houston, TX 77030, USA
8Division of Infectious Disease and Immunology, Department of Medicine, University of 
Massachusetts Medical School, Worcester, Massachusetts 01605, USA
9Laboratory of Gene Regulation and Signal Transduction, Departments of Pharmacology and 
Pathology, University of California San Diego, School of Medicine, 9500 Gilman Drive, San 
Diego, CA 92093, USA
10Department of Physiology and Biophysics, Case Western Reserve University School of 
Medicine, Cleveland, OH 44106, USA
Users may view, print, copy, and download text and data-mine the content in such documents, for the purposes of academic research, 
subject always to the full Conditions of use:http://www.nature.com/authors/editorial_policies/license.html#terms
Correspondence should be addressed to Xiaoxia Li (lix@ccf.org) and Yinling Hu (huy2@mail.nih.gov).
12These authors contributed equally to this work.
Author contributions
B.M., C.W., T.H., M.G., H.Z., and K.B., performed the in vitro experiments; J.W.-B. and T.S. performed the in vivo experiments; 
L.F., G.N., X.Z., J.T., D.K., K.F., M.K., G.N, and G.D. contributed reagents and helped to design the experiments; Y.H. contributed 
reagents, helped to design experiments, and helped to edit the manuscript; X.L. conceived the study, oversaw the experiments, 
analyzed the data, and wrote the manuscript.
Competing financial interests statement
The authors have no competing financial interests to declare.
HHS Public Access
Author manuscript
Nat Commun. Author manuscript; available in PMC 2015 March 30.
Published in final edited form as:
Nat Commun. ; 5: 4977. doi:10.1038/ncomms5977.
Author M
anuscript
Author M
anuscript
Author M
anuscript
Author M
anuscript
11Department of Pathology, Case Western Reserve University School of Medicine, Cleveland, OH 
44106, USA
Abstract
The inflammasomes are multiprotein complexes that activate caspase-1 in response to infections 
and stress, resulting in the secretion of pro-inflammatory cytokines. Here we report that IKKα is a 
critical negative regulator of ASC-dependent inflammasomes. IKKα controls the inflammasome at 
the level of the adaptor ASC, which interacts with IKKα in the nucleus of resting macrophages in 
an IKKα kinase-dependent manner. Loss of IKKα kinase activity results in inflammasome 
hyperactivation. Mechanistically, the downstream nuclear effector IKKi facilitates translocation of 
ASC from the nucleus to the perinuclear area during inflammasome activation. ASC remains 
under the control of IKKα in the perinuclear area following translocation of the ASC/IKKα 
complex. Signal 2 of NLRP3 activation leads to inhibition of IKKα kinase activity through the 
recruitment of PP2A, allowing ASC to participate in NLRP3 inflammasome assembly. Taken 
together, these findings reveal a IKKi-IKKα-ASC axis that serves as a common regulatory 
mechanism for ASC-dependent inflammasomes.
Introduction
Inflammasomes are multiprotein complexes that contain a member of the nucleotide-binding 
domain leucine-rich repeat (NLR) or AIM2-like receptor (ALR) family, and are activated in 
response to a diverse range of microbial, stress and damage signals, triggering caspase-1 
activation and resulting in maturation of the pro-inflammatory cytokines interleukin (IL)-1β 
and IL-181–3. The NLRP3 inflammasome consists of NLRP3 linked via a homotypic pyrin 
domain (PYD) interaction to the inflammasome adaptor molecule apoptosis associated 
speck-like protein containing a C-terminal caspase-activation-and-recruitment (CARD) 
domain (ASC)4, 5. ASC interacts with pro-caspase-1 via a CARD domain6. NLRP3 is 
activated by a wide range of pathogen-associated molecular patterns (PAMPS) and danger-
associated molecular patterns (DAMPs), including the nucleoside adenosine triphosphate 
(ATP)7, nigericin7, double-stranded RNA8, monosodium urate (MSU) crystals9, and 
silica10–12, among others.
Despite the diversity of potential activators, NLRP3 activation in bone marrow-derived 
macrophages (BMDMs) requires two distinct signals13. First, the cell must be “primed” by 
an NF-κB-inducing ligand (signal 1), such as the toll-like receptor-4 (TLR4) ligand 
lipopolysaccharide (LPS), to increase the transcription/translation of inflammasome 
components, including NLRP3 and pro-IL-1β14–19. Several studies have demonstrated that 
other events also take place during this priming phase20–24, including the translocation of 
the inflammasome adaptor molecule ASC from the nucleus to the cytoplasm23 and the 
deubiquitination of NLRP320, 22. Following priming, a second activator (signal 2) initiates 
the final assembly of the inflammasome complex. Rapid NLRP3 inflammasome formation 
in response to extracellular ATP is mediated by the purinergic receptor P2X725–27.
While the inflammasome plays a critical role in host defense against microbial 
infections28–35, aberrant activation of the inflammasome has been implicated in the 
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pathogenesis of numerous human diseases36–40. Therefore, the process of inflammasome 
activation is tightly controlled. However, the exact mechanism by which inflammasome 
activation is regulated has remained controversial and unclear. We became interested in the 
role of IKKα in the regulation of inflammasome activity, since loss of IKKα kinase activity 
is associated with spontaneous inflammatory diseases41, 42 and cancer43, 44. Previously, Zhu 
et al reported on mice bearing a mutation in the ATP binding site of IKKα that resulted in 
loss of kinase activity (K44A)45. Beginning at approximately 3 months of age, these mice 
developed severe skin lesions and systemic inflammation, with the eventual development of 
spontaneous squamous cell carcinoma (SCC) of the lung42. Additionally, mice expressing 
an inactivatable variant of IKKα (AA), in which the activating phosphorylation sites serines 
176 and 180 were replaced with alanines, had increased susceptibility to bacterial- and LPS-
induced shock46. Moreover, loss of acinar cell IKKα triggers spontaneous pancreatitis in 
mice41
In the present paper, we explore a novel mechanism by which IKKα regulates the 
inflammasome activation that might contribute to the inflammatory phenotypes in mice with 
loss of IKKα or its kinase activity. Loss of IKKα kinase activity results in markedly 
enhanced NLRP3, AIM2 and NLRC4 inflammasome activation, with aberrant caspase-1 
activation and IL-1β secretion. Furthermore, chimeric mice with loss of IKKα kinase 
activity in the hematopoietic compartment have significantly increased in vivo responses to 
the NLRP3 stimuli LPS and MSU, as well as greater inflammation in the acute silica-
induced lung injury model. We show that IKKα controls the inflammasome at the level of 
the adaptor molecule ASC, which interacts with IKKα in in the nucleus of resting 
macrophages in an IKKα kinase-dependent manner. IKKi (IKK-related kinase) facilitates 
the translocation of ASC from the nucleus to the perinuclear area during both NLRP3 
(IRAK1/2-dependent) and AIM2 (IRAK1/2-independent) inflammasome activation. ASC 
remains under the control of IKKα in the perinuclear area following translocation of the 
ASC/IKKα complex. Signal 2 of NLRP3 activation leads to the inhibition of IKKα kinase 
activity through the recruitment of phosphatase PP2A, allowing dissociation of ASC from 
IKKα for participation in NLRP3 inflammasome assembly. Consistently, ASC is also 
released from IKKα during AIM2 and NLRC4 inflammasome activation. In summary, we 
identify a novel IKKi-IKKα-ASC axis that serves as a common regulatory mechanism to 
control ASC-containing inflammasomes.
Results
Loss of IKKα kinase activity leads to inflammasome hyperactivation
We first examined NLRP3 inflammasome activation in bone marrow-derived macrophages 
(BMDMs) from IKKα K44A mice and WT controls. Surprisingly, treatment with LPS alone 
was sufficient to cause cleavage of pro-caspase-1 in IKKα K44A BMDMs, whereas both 
LPS+ATP were needed for caspase-1 activation in WT BMDMs (Fig. 1a). Furthermore, 
combined treatment with LPS+ATP led to increased inflammasome activity in IKKα K44A 
BMDMs compared to that in control cells (Fig. 1a,b). Furthermore, ATP-induced 
inflammasome activation was significantly increased in IKKα K44A cells primed with 
alternative TLR ligands, including Pam3CSK4, R848, and CpG (Supplementary Fig. 1a). 
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Moreover, LPS alone was able to induce the interaction between ASC and pro-caspase-1 in 
IKKα K44A BMDMs, while in WT BMDMs the interaction was only detectable following 
treatment with both LPS+ATP (Fig. 1c). It is important to note that the increased 
inflammasome activity in IKKα K44A BMDMs was not due to higher basal levels of 
inflammasome proteins, as pro-caspase-1, ASC, NLRP3, and pro-IL-1β levels were 
comparable between IKKα K44A and WT cells (Fig. 1a). One consideration is the possible 
impact of IKKα on NFκB activation. Consistent with previous studies47, NF-κB activation 
was actually comparable and even slightly decreased in IKKα K44A BMDMs, as indicated 
by IκBα phosphorylation and degradation (Supplementary Fig. 1b). Furthermore, we 
observed enhanced ATP-induced inflammasome activation following only 10 minutes of 
LPS priming in IKKα K44A BMDMs (Fig. 1d)21, 22, 24. Additionally, IKKα K44A cells pre-
treated with cyclohexamide showed significant caspase-1 activation following LPS 
stimulation alone, and greater caspase-1 activation than controls following LPS+ATP 
treatment, indicating that the enhanced inflammasome activation in IKKα K44A cells was 
not dependent on new protein synthesis (Supplementary Fig. 1c). Together, these findings 
strongly suggest that the inflammasome hyper-activation observed in IKKα K44A cells is 
due to a direct role of IKKα in inflammasome regulation. Consistently, IKKα AA BMDMs 
also showed enhanced inflammasome activation compared to controls (Fig. 1e).
Given the strong NLRP3 hyper-activation observed in cells with loss of IKKα kinase 
activity, we next sought to determine whether IKKα might also regulate other 
inflammasomes. IKKα K44A cells infected with the NLRC4 activator S. typhimurium29 
showed greatly enhanced caspase-1 activation (Fig. 1f). In addition, when IKKα K44A and 
IKKα AA BMDMs were transfected with the AIM2 ligand poly(dA:dT)28, 32, 34, both IKKα 
mutants showed increased AIM2 activation (Fig. 1g). Together, these data suggested that 
IKKα serves a critical regulatory role for the NLRP3, NLRC4 and AIM2 inflammasomes.
IKKα negatively regulates the inflammasome in vivo
To characterize the in vivo consequence of the inflammasome hyperactivity that we 
observed in IKKα K44A BMDMs, we generated bone marrow chimeric mice with a wild-
type background that received either WT or IKKα K44A bone marrow. While LPS alone is 
not sufficient to activate the inflammasome in wild-type macrophages in vitro, intra-
peritoneal administration of LPS in mice leads to an NLRP3-dependent response7, 14, 27. We 
found that following treatment with LPS, serum levels of IL-1β but not TNF-α were 
significantly higher in K44A→WT mice, and re-stimulation of K44A→WT splenocytes in 
vitro resulted in dramatically higher IL-1β production (Fig. 2a,b). Similarly, intra-peritoneal 
treatment of chimeric mice with monosodium urate (MSU) crystalsresulted in increased 
neutrophil influx in K44A→WT mice, as well as higher serum levels of IL-1β(Fig. 2c). We 
next sought to verify these findings of in vivo NLRP3 hyperactivity using a silica-induced 
acute lung injury model. Using this model, both K44A→WT and control mice received 
intra-tracheal administration of sterilized silica dust. Thirty-six hours after silica exposure, 
bronchoalveolar lavage (BAL) fluid from K44A→WT mice contained significantly higher 
concentrations of IL-1β (Fig. 2e). In addition, histopathologic analysis of K44A→WT lungs 
revealed greater pulmonary inflammation than WT→WT lungs (Fig. 2d). In support of these 
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in vivo studies, inflammasome hyperactivation was also observed ex vivo in LPS-primed 
IKKα K44A macrophages in response to silica, MSU, and alum (Supplementary Fig 1d).
IKKα kinase activity is required for interaction with ASC
Since both in vitro and in vivo studies showed a profound loss of inflammasome regulation 
in the absence of IKKα kinase activity, we further investigated the interaction between 
IKKα and the inflammasome pathway. Co-immunoprecipitation studies in HEK293 cells 
co-transfected with ASC and either IKKα WT or IKKα K44A indicated that ASC interacts 
with IKKα WT but not IKKα K44A (Fig. 3a). Similarly, in primary BMDMs, ASC co-
immunoprecipitated with endogenous IKKα WT, but failed to pull down IKKα K44A (Fig. 
3b), indicating that IKKα constitutively interacts with ASC and the kinase activity of IKKα 
is required for this interaction. Importantly, we found that the IKKα-ASC interaction was 
nearly abolished upon treatment with LPS plus ATP (Fig. 3b,c and Supplementary Fig. 2a–
c) or the bacterial pore-forming toxin gramicidin (Fig. 3c). Furthermore, pre-treatment with 
5 mM glycine attenuated LPS plus ATP-induced cell death but not the dissociation of ASC 
from IKKα, indicating that the observed dissociation was not secondary to cytotoxicity 
(Supplementary Fig. 2a). LPS+ATP treatment was also able to induce the dissociation of 
ASC from IKKα in caspase-1−/− macrophages (Supplementary Fig. 2b). Infection with S. 
typhimurium or transfection with poly(dA:dT) also led to the dissociation of ASC from 
IKKα (Fig. 3d), mirroring the results obtained with NLRP3 activators (Figs. 3b,c). In light 
of the constitutive interaction of IKKα with ASC, we reasoned that IKKα might be 
controlling ASC at the level of subcellular localization, which has been reported to be 
important for inflammasome regulation23. In resting WT BMDMs, ASC was located almost 
exclusively in the nucleus, while in IKKα K44A BMDMs ASC was primarily located in the 
perinuclear area (Fig. 3e). Following stimulation of WT cells with LPS, ASC translocated to 
the perinuclear area, akin to what was observed in resting IKKα K44A cells (Fig. 3e). In 
marked contrast, stimulation of IKKα K44A cells with LPS resulted in the formation of ASC 
perinuclear specks (Fig. 3e). Importantly, the perinuclear ASC specks that formed in 
response to LPS treatment alone in IKKα K44A BMDMs co-stained with caspase-1 FLICA, 
indicating that these structures were participating in inflammasome assembly (Fig. 3e). The 
addition of LPS+ATP resulted in the formation of active ASC specks in both wild-type and 
IKKα K44A cells, while quantification revealed significantly more specks in IKKα K44A 
cells compared to controls (Fig. 3e). These findings suggest that IKKα regulates 
inflammasome activation at least in part by controlling the subcellular localization of ASC, 
and that in the absence of this regulation ASC is released to the perinuclear area, resulting in 
qualitative and quantitative inflammasome hyperactivity.
Interestingly, although LPS+ATP induced hyperactivation of the inflammasome in IKKα AA 
macrophages (Fig. 1e,g), ASC was actually located almost exclusively in the nucleus in 
resting IKKα AA cells (Fig. 3e). However, stimulation of IKKα AA cells with LPS alone also 
resulted in the formation of ASC perinuclear specks that co-stained with caspase-1 FLICA 
(Fig. 3e). Consistently ASC retained the interaction with IKKα AA at resting state, while the 
interaction was abolished upon LPS stimulation (Supplementary Fig. 2c). Furthermore, 
quantification revealed significantly more LPS+ATP-induced specks in IKKα AA cells 
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compared to wild-type cells (Fig. 3e). Taken together, these results support the critical role 
of IKKα in the regulation of inflammasome activation.
S193 and S16 of ASC are required for interaction with IKKα
In order to better understand the mechanism by which IKKα exerts control over, we 
screened the serine residues on ASC. We mutated 12 serine residues in ASC to alanine and 
co-expressed the mutants with IKKα in 293 cells. We identified two sites on ASC that when 
mutated have altered interaction with IKKα. While one site (S193A) showed a complete 
loss of interaction with IKKα, another site (S16A) had a moderate reduction in interaction 
with IKKα (Fig. 4a). We then immunoprecipitated wild-type ASC, S193A and S16A from 
293 cells co-transfected with IKKα WT or IKKα K44A, followed by in vitro kinase assay. 
Co-expression of wild-type ASC with IKKα WT but not IKKα K44A resulted in 
phosphorylation of ASC (Fig. 4b). While S193A showed a complete loss of phosphorylation 
of ASC evident by the in vitro kinase assay, S16A had a moderate reduction in ASC 
phosphorylation (Fig. 4b). Since S193 is required for the interaction of ASC with IKKα, 
these results indicate that the interaction of ASC with kinase-active IKKα is important for 
ASC phosphorylation.
To examine the impact of S193A and S16A on inflammasome activation, we retrovirally 
infected ASC−/− macrophages with wild-type ASC, S193A and S16A. Wild-type ASC 
interacted with endogenous IKKα, retained the interaction in the presence of LPS, and 
dissociated with IKKα upon stimulation with LPS+ATP (Fig. 4c). In contrast, S193A lost 
interaction with IKKα, while S16A retained interaction with endogenous IKKα, but 
dissociated with IKKα upon LPS stimulation (Fig. 4c). In ASC−/− macrophages restored 
with wild-type ASC, ASC was located almost exclusively in the nucleus at resting state, 
whereas in S193A cells the majority of ASC was located in the perinuclear area (Fig. 4d). 
These results indicate that loss of interaction of S193A with IKKα released S193A from the 
nucleus, which is similar to the phenotype of ASC in IKKα K44A cells. Thus, S193 is a 
critical residue for the constitutive interaction of ASC with IKKα, which is required for the 
sequestration of ASC in the nucleus. In contrast, S16A only translocated to the perinuclear 
area in response to LPS stimulation, indicating that the interaction of S16A with IKKα was 
sufficient to retain S16A in the nucleus at resting state, mirroring the results from IKKα AA 
cells (Fig. 4d). However, stimulation of either S193A or S16A cells with LPS alone was 
sufficient for the formation of ASC perinuclear specks associated with inflammasome 
activation (Fig. 4d). Consistently, LPS alone was sufficient to cause cleavage of pro-
caspase-1 in ASC−/− macrophages infected with S193A and S16A, but not with wild-type 
ASC (Fig. 4e). Furthermore, treatment of S193A and S16A cells with LPS+ATP resulted in 
increased inflammasome activation compares to controls (Fig. 4e,4f). Thus, S16 is a critical 
residue required for the sustained interaction between IKKα-ASC after LPS-induced 
nuclear-cytoplasmic translocation, which is essential for IKKα-mediated ASC sequestration 
at the perinuclear area. Given that AIM2 inflammasome activation was also regulated by 
IKKα-mediated control of ASC (Fig. 3d), we extended this study by evaluating the impact 
of the S193A and S16A mutations on AIM2 activation. Transfection of S193A and S16A 
cells with poly(dA:dT) resulted in significantly enhanced AIM2 inflammasome activation 
(Fig. 4g).
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ATP inhibits IKKα and releases ASC
LPS alone was able to activate the inflammasome in IKKα K44A and IKKα AA BMDMs 
(Fig. 3e), suggesting that ATP acts to remove the inhibitory effect of IKKα on ASC in wild-
type cells. Given that IKKα dissociates from ASC upon LPS+ATP stimulation (Fig. 3b), we 
hypothesized that the second signal provided by ATP leads to the release of ASC from 
IKKα. Previous studies have shown that extracellular ATP requires the purinergic receptor 
P2X7R to induce inflammasome activation26, and pre-treatment with the P2X7R antagonist 
AZ10606120 (AZ) indeed prevented pro-caspase-1 cleavage in response to LPS+ATP (Fig. 
5a). Pre-treatment with AZ prevented the dissociation of IKKα from ASC upon treatment 
with LPS+ATP (Fig. 5a). Consistent with this, in P2X7R−/− BMDMs, ASC retained 
interaction with IKKα after treatment with LPS+ATP (Fig. 5b). As a consequence, pro-
caspase-1 cleavage was also abolished in P2X7R−/− cells following treatment with LPS
+ATP (Fig. 5c). Considering the fact that the IKKα K44A mutant failed to interact with 
ASC, the ATP/P2X7R-dependent dissociation of ASC from IKKα could be due to an impact 
on IKKα kinase activity. In support of this, BMDMs pre-treated with ATP had reduced 
phosphorylation of IKKα and IκBα in response to LPS treatment (Fig. 5d). To confirm the 
inhibition of IKKα kinase activity by NLRP3 stimuli, we performed an in vitro kinase assay 
using IKKα immunoprecipitated from LPS stimulated BMDMs that were pre-treated with 
DMSO, ATP, or nigericin. In this assay, both ATP and nigericin dramatically attenuated 
LPS-induced IκBα phosphorylation by IKKα (Fig. 5e). Furthermore, to determine whether 
ATP signaling was sufficient to inhibit the activity of activated IKKα, we performed in vitro 
kinase assay using LPS-primed macrophages treated with ATP. We found that the kinase 
activity of IKKα was still dramatically attenuated (Supplementary Fig. 3a). In addition, the 
inhibition of IKKα kinase activity by ATP was not secondary to caspase-1-dependent cell 
death, as pre-treatment with the caspase-1 inhibitor zYVAD did not prevent ATP-mediated 
IKKα inhibition (Supplementary Fig. 3b). Moreover, ATP-mediated IKKα inhibition was 
completely abolished in P2X7R−/− BMDMs (Supplementary Fig. 3b). Taken together, these 
data indicate that the second signal provided by extracellular ATP attenuates IKKα kinase 
activity, thus releasing ASC from the inhibitory action of IKKα and allowing ASC to 
participate in inflammasome assembly.
We next sought to explore the mechanism by which ATP-P2X7R signaling inhibits IKKα 
kinase activity. It was previously reported that the serine/threonine phosphatase PP2A 
directly dephosphorylates IKKα, and that this event decreases IκBα phosphorylation by 
IKKα48. In addition, others have reported that inhibition of PP2A and another closely 
related phosphatase, PP1, greatly diminished inflammasome activation in macrophages49. 
We therefore speculated that PP2A might play a role in ATP-mediated IKKα inhibition. We 
found that PP2A indeed co-immunoprecipitated with IKKα following treatment with LPS
+ATP, but not in resting cells or in response to LPS alone (Fig. 6a). Pre-treatment of 
BMDMs with the PP2A inhibitor okadaic acid and P2X7R inhibitor AZ prevented the 
interaction between IKKα and PP2A, and also abrogated the dissociation of ASC from 
IKKα (Fig. 6a). Pre-treatment with okadaic acid resulted in a dose-dependent decrease in 
inflammasome activation in response to LPS+ATP (Fig. 6b,c). In addition to ATP, the 
NLRP3 activator nigericin also induced interaction between PP2A and IKKα, while okadaic 
acid prevented this interaction (Fig. 6d) and led to a dose-dependent decrease in nigericin-
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induced caspase-1 cleavage (Fig 6e). Furthermore, PP2A knockdown substantially 
attenuated caspase-1 activation (Fig. 6f). Importantly, the decreased NLRP3 inflammasome 
activity observed in response to okadaic acid and PP2A knockdown was not due to an 
indirect impact on LPS signaling, as TNF-α secretion was unaffected (Fig. 6c). Instead, we 
found that PP2A knockdown abolished ATP-mediated IKKα inhibition (Supplementary Fig. 
3c) suggesting that PP2A plays a direct role in inhibiting IKKα in response to signal 2 of 
NLRP3 activation. We further found that blocking either K+ efflux or Ca2+ mobilization 
abolished the ATP- and nigericin-induced recruitment of PP2A to IKKα, suggesting that 
these cellular events, which are reported to be downstream of a multitude of NLRP3 
activators50, 51, may converge on PP2A-IKKα–ASC(Supplementary Fig. 3d). However, 
while PP2A activity was required for NLRP3 activation, PP2A knockdown had no effect on 
AIM2 inflammasome activation (Fig. 6g). Collectively, these data suggest that in LPS-
primed macrophages, ATP and nigericin activate PP2A to inhibit IKKα, releasing ASC for 
participation in NLRP3 inflammasome formation.
IKKi facilitates ASC nuclear-to-cytoplasmic translocation
One important question is how LPS induces ASC-IKKα translocation. IRAK1 and IRAK2 
are critical downstream mediators of the IL1-R/TLR pathway52–54, and a role for IRAK1 in 
acute NLRP3 inflammasome priming has recently been reported21, 24. We found that 
inflammasome activation in response to treatment with LPS for 4 hours followed by ATP 
was completely abolished in IRAK1/2−/− BMDMs (Supplementary Fig. 4a–c,e). IRAK1/2 
were also required for LPS-induced translocation of ASC-IKKα (Supplementary Fig. 5a). 
However, deficiency of IRAK1/2 had no impact on perinuclear ASC speck formation in 
response to poly(dA:dT) (Supplementary Fig. 4d–e). We next asked what signaling 
molecule(s) might be acting downstream of IRAK1/2 to promote NLRP3 inflammasome 
activation. Furthermore, given that IRAK1/2 were actually dispensable for AIM2 
inflammasome activation, we also hypothesized that there might be a common effector 
promoting ASC translocation during the activation of ASC-dependent inflammasomes. We 
focused on several of the kinases implicated in TLR4-IRAK1/2 downstream signaling, 
including TAK154, NIK55, Mnk1/252 and IKKi56. Among the tested kinases (Supplementary 
Fig. 6a), we found that only IKKi deficiency resulted in dramatic reduction of 
inflammasome activation in response to LPS+ATP treatment, while having minimal impact 
on TNF-α secretion (Fig. 7a,b). We found that IKKi deficiency also resulted in decreased 
AIM2 activation (Fig. 7c). Consistently, IKKi deficiency resulted in greatly diminished ASC 
translocation in response to both LPS and poly(dA:dT), as well as decreased speck 
formation (Fig. 7d), suggesting that IKKi might be the common effector for ASC-dependent 
inflammasome activation.
S58 of ASC is a critical for IKKi-mediated ASC translocation
We further investigated how IKKi mediates inflammasome activation. Immunostaining 
showed that while IKKi was in the cytoplasm of untreated cells, LPS stimulation induced 
partial translocation of IKKi into the nucleus, some of which co-localized with ASC, while 
further treatment with ATP dispersed IKKi back to the cytoplasm (Fig. 7d). Co-
immunoprecipitation experiments showed that LPS stimulation induced the interaction of 
IKKi with ASC, which was abolished upon ATP treatment (Fig. 7e). In addition, the LPS-
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induced interaction between IKKi and ASC was completely abolished in IRAK1/2−/− 
BMDMs (Supplementary Fig. 5b). Since IKKi interacted with ASC and co-localized with 
ASC in the nucleus in response to LPS stimulation, we hypothesized that IKKi might 
directly regulate ASC. To test the functional link between IKKi and ASC, ASC was co-
expressed with wild-type IKKi or kinase dead IKKi (IKKi-KD). We found that co-
expression of wild-type ASC with wild-type IKKi but not IKKi-KD resulted in 
phosphorylation of ASC (Fig. 8a), implying a functional role of IKKi in mediating ASC 
phosphorylation. In search of the residue(s) in ASC required for IKKi-mediated 
phosphorylation, we became interested in residue S58 of ASC due to the fact that the S58A 
mutant was reported to have substantially reduced inflammasome activation57. We found 
that ASC−/− macrophages restored with S58A showed abolished inflammasome activation in 
response to LPS+ATP stimulation (Supplementary Fig. 6b). Importantly, compared to wild-
type ASC, S58A showed abolished phosphorylation when co-expressed with IKKi (Fig. 8a), 
indicating that residue S58 is required for IKKi-induced ASC phosphorylation.
Since IKKi is required for LPS-induced ASC nuclear-cytoplasmic translocation, we tested 
the S58A restored macrophages by confocal imaging. Similar to wild-type ASC, the S58A 
mutant was mostly retained in the nucleus of resting cells (Fig. 8b). While LPS induced 
translocation of wild-type ASC to the perinuclear area, S58A remained in the nucleus upon 
LPS stimulation (Fig. 8b). Furthermore, LPS+ATP-induced ASC speck formation was 
significantly reduced in S58A cells (Fig. 8b). Consistently, S58A remained in complex with 
IKKα even upon treatment with LPS+ATP (Fig. 8c). Moreover, AIM2 activation was also 
attenuated in S58A cells (Fig. 8b). Taken together, these results strongly suggest that S58 is 
a critical residue for ASC translocation to the perinuclear area, which might be achieved 
through IKKi-mediated phosphorylation of this residue.
Since S58A failed to translocate in response to LPS, we wondered whether this mutation 
would cause sequestration of S193A or S16A in the nucleus. Thus, we generated 
S193AS58A and S16AS58A double mutations and retrovirally introduced them into ASC−/− 
macrophages, along with S193A and S16A. In these restored cells, LPS alone induced 
inflammasome activation in S193A, S16A and S193AS58A, whereas S16AS58A failed to 
promote inflammasome activation even when stimulated with LPS+ATP (Fig. 8d). Similar 
to S193A, S193AS58A was also perinuclear in resting cells and showed ASC speck 
formation in response to LPS, indicating that S58A mutation had no reversal effect on ASC 
S193A (Fig. 8e). Consistent with our findings from NLRP3 activation (Fig. 8d), we found 
that in S58A and S16AS58 cells, poly(dA:dT) resulted in dramatically decreased caspase-1 
cleavage, while S193AS58A cells showed increased activation (Fig. 8f). Thus, the S58A 
mutation caused S16A sequestration in the nucleus, indicating that IKKi-mediated ASC 
phosphorylation through S58 is required for S16A translocation and consequent 
inflammasome activation.
Discussion
Although the inflammasomes play a central role in host defense and in many common 
human diseases, the regulatory mechanisms governing these important complexes have 
remained unclear. In this study, we identified IKKα as a critical negative regulator of ASC-
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containing inflammasomes. IKKα constitutively interacts with the common inflammasome 
adaptor molecule ASC in a kinase activity-dependent manner, and loss of IKKα kinase 
activity results in hyperactivation of the NLRP3, AIM2, and NLRC4 inflammasomes. 
Mechanistically, the IKK-related kinase IKKi directly participates in NLRP3 inflammasome 
activation via LPS-induced interaction with ASC, driving the translocation and perinuclear 
re-organization of the ASC/IKKα complex. Following translocation of the ASC/IKKα 
complex, ASC remains under the control of IKKα in the perinuclear area. Signal 2 of 
NLRP3 activation leads to the inhibition of IKKα kinase activity through recruitment of 
PP2A, allowing dissociation of ASC from IKKα for participation in inflammasome 
assembly. Consistently, AIM2 and NLRC4 inflammasome activators also result in 
dissociation of ASC from IKKα. Together, these findings reveal a novel IKKi-IKKα-ASC 
axis that serves as a common regulatory mechanism to govern the ASC-dependent 
inflammasomes.
One question that arises from our study is the precise mechanism by which IKKα sequesters 
ASC in the nucleus of resting macrophages. In fact, it is possible that there is some degree of 
IKKα kinase activity in resting macrophages. It was previously reported that purified IKKα 
underwent autophosphorylation, whereas a kinase-inactive version of IKKα, in which the 
ATP binding site was mutated (K44M), showed no autophosphorylation58. In the same 
report, it was shown that a related kinase, IKKβ, although expressed in equivalent amounts, 
showed very weak autophosphorylation. We found that ASC is mainly located in the 
perinuclear area of resting IKKα K44A macrophages but is retained in the nucleus of IKKα 
AA cells, suggesting that IKKα might have basal activity that is independent of activating 
phosphorylation at S176/180, and that this activity is critical for the control of ASC. 
However, we cannot exclude the possibility that the differential impact of IKKα K44A 
versus IKKα AA on ASC localization in resting cells might also reflect structural 
differences. In addition to this IKKα-mediated regulation of ASC in the nucleus, we further 
found that IKKα continues to control ASC after LPS-induced perinuclear re-organization. It 
is interesting to note that although S16A was retained in the nucleus of resting cells, this 
mutation allowed LPS-induced NLRP3 inflammasome activation without ATP, which 
resembles the phenotype of ASC in IKKα AA cells. Both IKKα AA and S16A macrophages 
also exhibit hyperactivation of the AIM2 and NLRC4 inflammasomes, implying that IKKα-
mediated ASC sequestration at the perinuclear area is part of the common regulatory 
mechanism for the control of ASC-dependent inflammasomes following ASC/IKKα 
translocation.
Most previous studies in the field have viewed priming of the NLRP3 inflammasome as a 
passive process that permits the generation of rate-limiting components, in particular 
NLRP314–19. Several recent studies have demonstrated that other critical events also take 
place during this phase20–24. Our own studies suggest that “signal 1” of NLRP3 activation 
initiates a cascade of signaling events that results in the movement of ASC-IKKα from the 
nucleus. Indeed, it was recently reported that the TLR pathway molecule IRAK1 plays a 
crucial role in facilitating ASC nuclear-to-cytosolic translocation during NLRP3 priming24. 
We found that while IRAK1/2 double deficiency completely abolished NLRP3 activation, it 
had minimum impact on LPS-induced NLRP3 and pro-caspase-1 expression 
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(Supplementary Fig. 4a–c), probably due to the fact that IRAK1/2-deficiency has little 
impact on TLR4-induced NFκB activation54.
Excitingly, we found that IKKi is critical for the nuclear-to-cytosolic translocation of ASC 
and for consequent NLRP3 inflammasome activation. We also discovered that IKKi is also 
important for AIM2 activation, suggesting that IKKi plays a unique role in mediating ASC 
translocation and perinuclear re-organization in response to diverse ligands (both TLR-
dependent and –independent), thus critically facilitating the activation of ASC-containing 
inflammasomesIt will be important to investigate whether AIM2 engages IKKi directly, or 
via additional intermediate molecules. An additional question posed by the finding that IKKi 
plays a central role in inflammasome activation is how TNF-α, which has also been shown 
to prime the NLRP3 inflammasome, might participate in inflammasome activation in an 
IKKi-dependent manner. Interestingly, IKKi has a well-described role in the TNF-α 
pathway, with TNF-α activating IKKi/TBK1 through a TAK1-IKKα/β-dependent 
pathway59, 60. Furthermore, this same pathway also induces IKKi upregulation via NF-kB-
mediated IKKi gene transcription61. Therefore, it is possible that IKKi also promotes TNFα-
induced priming. Future investigation is warranted to delineate the precise role of IKKi in 
this pathway.
The functional impact of IKKi on ASC was further investigated through the structure-
functional analysis of ASC. Interestingly, our data suggest that S58 might be a potential 
phosphorylation site for IKKi, since S58A showed abolished phosphorylation when co-
expressed with IKKi. Therefore, it is possible that this phosphorylation alters the 
conformation of ASC, or is critical for the interaction of ASC with a chaperone protein that 
then directly facilitates ASC translocation. It is also important to note that Syk and Jnk have 
recently been shown to direct phosphorylation of ASC, and that this phosphorylation is 
required for NLRP3 activation57. It is possible that Syk or Jnk might act on ASC after ASC-
IKKα translocation to the perinuclear area. These are important questions that should be 
addressed in subsequent studies.
Another important question in inflammasome biology is how diverse “signal 2” stimuli 
converge to activate the NLRP3 inflammasome13. Many cellular events have been proposed 
as key mediators of NLRP3 activation. Recently, K+ efflux51 and Ca2+ mobilization50 have 
also been shown to play crucial roles in response to many NLRP3 stimuli. Here, we 
demonstrated that the inhibition of IKKα and the subsequent dissociation of ASC from 
IKKα occurred in response to NLRP3 stimuli. In search of intermediate signaling molecules 
for “signal 2”-mediated IKKα inhibition, PP2A was a candidate because it was previously 
shown to directly inactivate IKKα48. We found that pharmacologic inhibition and 
knockdown of PP2A prevented ASC dissociation from IKKα, and attenuated inflammasome 
activation. We further found that blocking either K+ efflux or Ca2+ mobilization abolished 
ATP- and nigericin-induced recruitment of PP2A to IKKα, suggesting that these events 
converge on the PP2A-IKKα–ASC axis. Based on these findings, we propose that “signal 
2”-induced recruitment of PP2A to the IKKα-ASC complex results in IKKα inhibition and 
consequent liberation of ASC from IKKα. This liberated form of ASC may experience a 
conformational change, which is permissive for assembly of the inflammasome. It is 
important to point out that ASC was also released from IKKα during AIM2 inflammasome 
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activation. However, it remains unclear what drives the dissociation of ASC from IKKα for 
AIM2 activation, since PP2A was dispensable for the activation of AIM2. It is possible that 
some other phosphatase may act on IKKα during AIM2 activation, such as the closely 
related phosphatase PP1. Another possibility is that an intermediary molecule may act 
during AIM2 activation to disrupt IKKα-mediated suppression of ASC without the 
requirement for IKKα dephosphorylation, for example by competing with ASC. These will 
be important questions for future investigation.
Materials and Methods
Reagents
Ultrapure LPS (tlrl-pelps), Pam3CSK4 (tlrl-pms) and MSU (tlrl-msu) were purchased from 
Invivogen. LPS (E coli serotype 0111:B4), poly(dA:dT) (P0883), poly(I:C) (P1530) and 
ATP (A2383) were purchased from Sigma. Imject alum (77161) was purchased from 
Thermoscientific. Anti-caspase-1 (p20) antibody was generated as previously described by 
L. Franchi and G. Nunez. Anti-ASC (N-15)-R, anti-IKKα (SC–7218), anti-IKKα 
(SC-7182), anti-IRAK1 (H273), anti-Caspase1 p10 (M20), Anti-NLRP3 (H-66), Anti-IKKi 
(A-11) antibodies and normal rabbit IgG (SC-2027), normal mouse IgG (SC-2025) were 
purchased from Santa Cruz Biotechnology, Inc. Anti-ASC antibody (AL177) was purchased 
from Adipogen. Anti-ASC antibody (2EI-7) was purchased from Milipore. Anti-IKKα 
(14A321) was purchased from Millipore. Antibodies against phosphorylated Anti-IκBα 
(Ser-32/36), Anti-p-IKKα/β (Ser-176/180), Anti-IκBα (4812), Anti-GFP (2956), Anti-
PP2Ac (2259), Anti-IKKi (3416) and Mouse anti-rabbit conformation specific mAb (3678) 
were purchased from Cell Signaling. Anti-neutrophil antibody (NIMP-R14) and anti-IRAK2 
(ab62419) antibody were purchased from Abcam. Anti-IL-1β antibody (3ZD) was obtained 
from the Biological Resources Branch of the NIH. AZ10606120 (3323) and okadaic acid 
(1136) were purchased from Tocris. Silica (MIN-U-SIL 5) was a gift from US Silica. 
Antibodies for flow cytometry were purchased from eBiosciences: FITC-Gr-1 (RB6.8C5), 
PE-Cy7CD11b (M1/70), PCP-Ly6C (HK1.4), APC-F4/80 (BM8), and APC-Cy7-CD11c. 
Anti-Mouse (GAM) and Anti-Rabbit (GAR) secondary antibody were purchased from 
Thermo scientific. All antibodies were used at a dilution of 1:1000 unless otherwise 
specified.
Mice
6–12 week old age- and gender-matched IKKα K44A42, IKKα AA46, P2X7R−/−25, 
IRAK1−/−54, IRAK2−/−54, Caspase-1−/−62, IKKi−/−63, and NIK−/−64 mice were previously 
described. All studies were performed according to National Institutes of Health guidelines 
and were approved by the Institutional Animal Care and Use Committee of the Cleveland 
Clinic, Case Western Reserve University, and the National Cancer Institute. For in vivo 
experiments, we performed a power analysis based on our previous experience with each 
technique, including effect size and variation within and between experiments. Mice were 
numbered and then treated and sacrificed according to a randomized protocol.
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Generation of bone marrow chimeric mice
6–10 week old age- and gender-matched WT recipient mice were gamma-irradiated with 
950 rad using the 137Cs irradiator facility at the Frederick National Laboratory. Recipient 
mice were then injected i.v. with 1 × 106 WT or IKKα K44A BM cells isolated from 10-
week old female mice. Single cell suspensions of BM cells were prepared by passing 
dissociated long bone cells through a 40 um strainer followed by washing with PBS.
LPS shock and peritonitis induction
Mice were injected intra-peritoneally with either 30 mg/kg Ultrapure LPS (Invivogen) or 
100 mg MSU (Invivogen) resuspended in a total volume of 100 ul endotoxin-free PBS. 
Serum was collected 2 hours post-LPS treatment and 5 hours-post MSU treatment. 
Peritoneal lavage was carried out at the same as serum collection, and used 5 mL total 
volume PBS. Total lavage volume was spun and cells were counted and stained surface 
stained for Gr-1, CD11b, Ly6c, F4/80, and CD11c for flow cytometric analysis.
Silica-induced lung inflammation
Mice were anesthetized using a combination of ketamine (80 mg/kg) and xylazine (10 mg/
kg). Silica-induced lung injury was then induced by instillation of 1 mg sterilized silica 
particles in 100 ul of sterile saline as previously described65. BAL fluid was collected from 
anesthetized mice using a 0.8 ml PBS wash of the lungs (5 times) with a 22-gauge catheter.
Cell Preparation
Unless otherwise indicated, all cells were cultured at 37° C. Bone marrow-derived 
macrophages (BMDMs) were obtained from bone marrow of tibia and femur and cultured 
by DMEM with 20% FBS and 30% L929 cell-conditioned medium and penicillin/
streptomycin for differentiation and proliferation of BMDMs. Cells were differentiated for 5 
days, and then re-plated and used for experiments the following day. 293T cells were 
purchased from ATCC (Manassas, VA). Immortalized WT and ASC−/− BMDMs were 
previously described10.
Retroviral production and restoration of immortalized macrophages
For infection of immortalized macrophages, viral supernatants were collected 36 hours after 
transfection of Phoenix cells with 5 μg empty vector, mASC WT, mASC S193A, mASC 
S16A, mASC S58A, mASC S58AS193A and mASC S58AS16A, which had all been cloned 
into pMx-IP vector. After 48 hours of infection, puromycin (10 μg/ml) was added to the 
cells to select for restored cells. Mouse ASC mutant constructs were designed using the 
following primer pairs: ASC S16A forward-GGACGCTCTTGAAAACTTGG 
CAGGGGATGAAC, ASC S16A reverse- 
GTTCATCCCCTGCCAAGTTTTCAAGAGCGTCC; ASC S193A forward- 
GTGATGGACCTGGAGCAGGCCTGAGAATTCAAGC, ASC S193A reverse- 
GCTTGAATTCTCAGGCCTGCTCCAGGTCCATCAC; ASC S58A forward- 
CAAACTTGTCGCCTACTATCTGGAGTCGTATGGCTTGG; ASC S58A reverse- 
CCAAGCCATACGACTCCAGATAGTAGGCGACAAGTTTG.
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Inflammasome activation
BMDMs were plated in 6-well plates at a concentration of 2.0 × 106 cells per well the day 
before the experiment. The day of the experiment, cells were primed with LPS (1 μg/ml), 
Pam3CSK4 (1 μg/ml), R848 (1 μg/ml), or CpG-B (1 μg/ml) for the indicated time. Medium 
was then supplemented with ATP (5 mM) for indicated timepoints. For AIM2 
inflammasome activation, cells were transfected with 1.5 μg/ml poly(dA:dT) using 
lipofectamine 2000 transfection reagent in OPTI-MEM media. For NLRC4 inflammasome 
activation, Salmonella typhimurium (SL 1344) was added at an MOI of 50, and after 30 
minutes gentamycin was added to the medium. For all experiments, cell-free supernatant 
was then either collected for ELISA analysis, or cell lysates and supernatants were collected 
together for immunoblotting by the addition of 1% Nonidet-P40 supplemented with 
complete protease inhibitor ‘cocktail’ (Roche) and 2 mM dithiothreitol directly to the well. 
Cells were scraped and lysed on ice for 30 minutes, then spun at 13,000 rpm. Protein 
concentration was measured. 4X Laemlli buffer was then added, samples were boiled and 
approximately 20 μg of sample was run on a 12% or 15% SDS-PAGE gel.
Immunoprecipitation and pull-down assay
BMDMs were plated in a 15 cm dish 1–2 days before the experiment at a concentration of 1 
× 106 cells per ml. The day of the experiment, cells were stimulated as indicated. After 
washing with cold PBS, cells were lysed in 0.5 ml of lysis buffer (50 mm Tris-HCL, pH 7.4, 
150 mm NaCl, 1% Triton, 1 mm EDTA, 5 mm NaF, 2 mm NaVO3, 1 mm PMSF, 1× 
complete protease inhibitors). Cell lysates were cleared by centrifugation at 13,000 rpm for 
10 min, and insoluble debris was discarded. Then supernatants were precleared by 
incubation with agarose beads for 1 h at 4 °C followed by centrifugation at 3000 rpm. For 
co-immunoprecipitations, precleared supernatants were incubated with 20 μl of protein A-
Sepharose beads with antibody at 4 °C overnight, and beads were washed with 1 ml of lysis 
buffer 5 times before dissolved in 40 μl of Laemmli buffer.
Immunoblotting
Whole cell lysates and or immunoprecipitates were dissolved in Laemmli buffer and 
resolved by 10%–15% SDS-PAGE. After electrophoresis, separated proteins were 
transferred onto polyvinylidene difluoride membrane (Millipore). For immunoblotting, the 
polyvinylidene difluoride membrane was blocked with 5% nonfat milk. After incubation 
with specific primary antibody, horseradish peroxidase-conjugated secondary antibody was 
applied. The positive immune reactive signal was detected by ECL (Amersham 
Biosciences).
Confocal Analysis
BMDMs were treated as indicated. Cells were then fixed in 4% paraformaldehyde for 10–15 
min, washed, and blocked with Signal Enhancer. Cells were reacted with anti-ASC, anti-
IKKi and caspase-1 FLICA (FAM-YVAD-FMK), washed, and incubated with Alexa-488 
(green) or Alexa-555 (red) secondary antibody.
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Biochemical assays
Mouse IL-1β and TNF-α in cell culture supernatants were measured using IL-1β and TNF-α 
Duo-Set kits purchased from R&D systems, and were used according to the manufacturer’s 
instructions. LDH was measured using the Cytotox 96 Non-Radioactive Cytotoxicity Assay 
(Promega).
In vitro kinase assays
Cells were washed twice with ice-cold PBS, and lysed using Co-IP buffer for 30 min on ice. 
Cell lysate (600 μl) was immunoprecipitated with indicated antibody in the presence of 
protein A-agarose beads overnight at 4°C with constant agitation. The beads were washed 
twice with Co-IP buffer following by two additional washes with kinase buffer (20 mM 
HEPES, pH 7.5, 10 mM MgCl2, 25m M NaCl, 20 mM β-glycerophosphate, and 10 mM 
sodium orthovanadate). Washed beads were incubated with 30 μl kinase buffer including 50 
μM of cold ATP, 5 μCi of radioactive ATP (γ-32P ATP) and with/without indicated 
substrate at 30°C for 30 min. The reaction was stopped by the addition of 4x sample buffer 
and heating for 5 min at 95°C. Proteins were subjected to SDS-PAGE, followed by 
autoradiography.
Statistics
Non-parametric statistical analysis was applied to all data sets. The P values of for all 
comparisons were determined by Mann-Whitney test unless otherwise noted. P<0.05 was 
considered to be significant. Unless otherwise specified, all center values represent the mean 
while error bars represent the s.e.m.
Supplementary Material
Refer to Web version on PubMed Central for supplementary material.
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Figure 1. 
IKKα is a negative regulator of the inflammasome (a) BMDMs from WT and IKKα K44A 
mice were either left untreated or treated with LPS (1 μg/ml) for 4 hours, 5 mM ATP (30 
min), or LPS (1 μg/ml) 4 hours + 5 mM ATP (30 min). Cell lysates and supernatants were 
collected together and were immunoblotted with the indicated antibodies. (b) Cell-free 
supernatants were collected from BMDMs that were either left untreated, or treated with 
LPS (1 μg/ml) for 4 hours, Pam3CSK4 (1 μg/ml) for 4 hours, LPS (1 μg/ml) 4 hours + 5 mM 
ATP (30 min), or Pam3CSK4 (1 μg/ml) 4 hours + 5 mM ATP (30 min). Levels of IL-1β and 
TNF-α were measured by ELISA. (c) BMDMs from WT and IKKα K44A mice were left 
untreated or treated with LPS (1 μg/ml) for 4 hours, or LPS (1 μg/ml) 4 hours + 5 mM ATP 
(30 min). Cell lysates were collected and immunoprecipitated with anti-ASC antibody or 
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control IgG antibody, followed by immunoblotting with the indicated antibodies. (d,e) 
BMDMs from WT and either IKKα K44A (d) or IKKα AA (e) mice were treated with LPS (1 
μg/mL) for 0, 10, 30, or 60 minutes, followed by the addition of 5 mM ATP for 30 minutes. 
(f) BMDMs from WT and IKKα K44A mice were infected with Salmonella typhimurium at 
a multiplicity of infection (MOI) of 50 for 0, 0.5, 1, or 2 hours. Cell lysates and supernatants 
were then collected together and immunoblotted with the indicated antibodies. (g) BMDMs 
from WT, IKKα K44A (left panel) and IKKα AA mice (right panel) were transfected with 
poly(dA:dT) (1.5 μg/ml) using lipofectamine 2000. After indicated times, cell lysates and 
supernatants were collected together and immunoblotted with the indicated antibodies. N.D. 
indicates not detectable, and “UN” indicates left untreated. Data are representative of at least 
five independent experiments. Error bars represent s.e.m. of technical replicates. * P <0.05 
by Mann-Whitney test.
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Figure 2. 
IKKα is a critical regulator of NLRP3 inflammasome activation in vivo (a,b) Irradiated WT 
mice received bone marrow from either WT or IKKα K44A mice. After six weeks of 
engraftment, chimeric mice received 30 mg/kg Ultrapure LPS in 100 μl PBS (i.p). Serum 
was collected after 2 hours and levels of IL-1β and TNF-α were measured by ELISA (a). 
Splenocytes were collected and cultured for 2 hours with or without re-stimulation with LPS 
(1μg/ml). Cell-free supernatants were collected and levels of IL-1β and TNF-α were 
measured by ELISA (b). (c) Chimeric mice as described in (a) received 1 mg MSU in 100 μl 
PBS (i.p.). Five hours later, peritoneal lavage was performed and infiltrating neutrophils 
were quantified (left panel). Serum was collected and IL-1β levels were determined by 
ELISA (right panel). (d,e) Chimeric mice as described in (a) received 1 mg sterilized silica 
by intra-tracheal instillation. Thity-six hours later, lungs were harvested and lung sections 
were stained with hematoxylin and eosin (upper panels) or with anti-neutrophil antibody 
(NIMP-R14) (lower panels); scale bar represents 50 μm (d). Broncho-alveolar lavage (BAL) 
was performed and IL-1β levels in cell-free BAL fluid was assessed by ELISA (e). N.D. 
indicates not detectable, and “UN” indicates left untreated. Data are representative of two 
independent experiments. n = 5 mice per group in each experiment. Error bars represent 
s.e.m. of biological replicates. * P <0.05 by Mann-Whitney test.
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Figure 3. 
IKKα regulates the inflammasome via interaction with ASC (a) HEK 293 cells were 
transfected with ASC and either GFP- IKKα WT or GFP-IKKα K44A using lipofectamine 
2000. Empty vector was used to normalize total plasmid transfected. Cells were then lysed, 
followed by immunoprecipitation with anti-ASC antibody and immunoblotting with the 
indicated antibodies. (b,c) BMDMs from WT and IKKα K44A mice (b) or WT mice only (c) 
were either left untreated or treated with LPS (1 μg/ml) for 4 hours, or LPS (1 μg/ml) 4 
hours + 5 mM ATP (30 min) (b), or either left untreated or treated with LPS (1 μg/ml) for 4 
hours, LPS (1 μg/ml) 4 hours + 5 mM ATP (30 min), or LPS (1 μg/ml) 4 hours + 1 uM 
gramicidin (30 min) (c). Cell lysates were then immunoprecipitated using anti-ASC 
antibody or control IgG antibody, and were immunoblotted with the indicated antibodies. 
(d) BMDMs from WT mice were transfected with poly(dA:dT) (1.5 μg/ml) using 
lipofectamine 2000 for 4 hours (left panel), or were infected with 50 MOI of S. 
typhimurium for indicated times (right panel). Cell lysates were then immunoprecipitated 
using anti-ASC antibody or control IgG antibody, and were immunoblotted with the 
indicated antibodies. (e) WT, IKKα K44A and IKKα AA BMDMs were either left untreated 
or treated with LPS (1 μg/ml) for 4 hours, or LPS (1 μg/ml) 4 hours + 5 mM ATP (30 min), 
then washed, fixed, and stained with anti-ASC antibody and caspase-1 FLICA (FAM-
YVAD-FMK). Images were then acquired using confocal microscopy with a 60X objective 
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and 4X enlargement; scale bars are 5 μm. Images were quantified by counting number of 
cells with ASC specks co-staining with caspase-1 FLICA as a percentage of total cells 
counted in three fields. (far right panel). “UN” indicates left untreated. Data are 
representative of at least four independent experiments. Error bars represent s.e.m. of 
technical replicates. * P <0.05 by Mann-Whitney test.
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Figure 4. 
S193 and S16 are critical residues on ASC for interaction with IKKα (a) HEK 293 cells 
were transfected with HA-IKKα and either WT ASC, S16A ASC, or S193A ASC using 
lipofectamine 2000. Empty vector was used to normalize total plasmid transfected. Cells 
were then lysed, followed by immunoprecipitation with anti-ASC antibody and 
immunoblotting with the indicated antibodies. (b) HEK 293 cells were transfected with HA-
IKKα or HA-IKKα K44A along with either WT ASC, S16A ASC, or S193A ASC using 
lipofectamine 2000. Empty vector was used to normalize total plasmid transfected. Cells 
were then lysed, followed by immunoprecipitation with anti-ASC antibody and in vitro 
kinase assay. (c,d) Immortalized ASC−/− macrophages retrovirally reconstituted with empty 
vector, WT ASC, S193A ASC, or S16A ASC were either left untreated or treated with LPS 
(1 μg/mL) for 4 hours, followed by 30 min 5 mM ATP when indicated. Cells were then 
lysed, followed by immunoprecipitation with anti-ASC antibody and immunoblotting with 
indicated antibodies (c), or cells were then washed, fixed, and stained with anti-ASC 
antibody and caspase-1 FLICA (FAM-YVAD-FMK). Images were then acquired using 
confocal microscopy with 60X magnification and 4X enlargement; scale bars are 5 μm (d). 
Images from were quantified by counting the number of cells with ASC specks co-staining 
with caspase-1 FLICA as a percentage of total cells counted in three fields. (e–g) 
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Retrovirally reconstituted ASC−/− macrophages from (c) were either left untreated or treated 
with LPS (1 μg/ml) for 4 hours, followed by 30 minutes of 5 mM ATP when indicated (e,f), 
or were transfected with poly(dA:dT) (1.5 μg/ml) using lipofectamine 2000 for 4 hours (g). 
Cell lysates and supernatants were then collected together and immunoblotted with the 
indicated antibodies (e,g), or were analyzed by ELISA (f). N.D. indicates not detectable, and 
“UN” indicates left untreated. Data are representative of at least four independent 
experiments. Error bars represent s.e.m. of technical replicates. * P <0.05 by Mann-Whitney 
test.
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Figure 5. 
ATP signaling throμgh P2X7R inhibits IKKα and releases ASC (a) BMDMs from WT mice 
were pre-treated with either DMSO or the P2X7R antagonist AZ10606120 (AZ) at a 
concentration of 10 nM for 30 min. Cells were then left untreated or treated with LPS (1 
μg/ml) for 4 hours, or LPS (1 μg/ml) 4 hours + 5 mM ATP (30 min). Cell lysates were 
immunoprecipitated with anti-ASC antibody or control IgG antibody, and immunoblotted 
with the indicated antibodies (upper panel). Some cell lysates that were not used for 
immunoprecipitation were immunoblotted with other antibodies as indicated (lower panel). 
(b,c) BMDMs from WT and P2X7R−/− mice were either left untreated or treated with LPS 
(1 μg/ml) for 4 hours, or LPS (1 μg/ml) 4 hours plus 5 mM ATP (30 min). Cell lysates were 
immunoprecipitated with anti-ASC antibody or control IgG antibody, and were then 
immunoblotted with the indicated antibodies (b). Cell lysates not used for 
immunoprecipitation were immunoblotted with the indicated antibodies (c). (d) BMDMs 
from WT mice were pre-treated with 5 mM ATP 15 minutes prior to treatment with LPS (1 
μg/ml) for 0, 15, 30, 60, or 120 minutes. Cells were then lysed and immunoprecipitated with 
anti-IKKα antibody. Immunoprecipitated proteins were eluted and immunoblotted for p-
IKKα/β and IKKα. Lysates obtained before immunoprecipitated were immunoblotted for p-
IκBα and Actin. (e) WT BMDMs were pre-treated with 5 mM ATP or 10 μM nigericin for 5 
minutes, then treated with LPS (1 μg/ml) for 0, 15, or 30 minutes. Cells were then lysed and 
immunoprecipitated with anti-IKKα antibody, followed by in vitro kinase assay using GST-
IκBα (1–317) as substrate. Data are representative of at least four independent experiments. 
Error bars represent s.e.m. of technical replicates. * P <0.05 by Mann-Whitney test.
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Figure 6. 
PP2A activity is required for NLRP3 inflammasome activation (a,d) BMDMs from WT 
mice were pre-treated with DMSO, 100 nm okadaic acid (OA), or 10 nM AZ10606120 for 
15 minutes. Cells were then left untreated or treated with LPS (1 μg/ml) for 4 hours, LPS (1 
μg/ml) 4 hours plus 5 mM ATP (30 min), LPS (1 μg/ml) 4 hours plus 5 mM ATP (30 min) 
plus OA (100nM) or LPS (1 μg/ml) 4 hours plus 5 mM ATP (30 min) plus AZ10606120 (10 
nM) (a) or 10 uM nigericin (30 min) (d). Cell lysates were immunoprecipitated using anti-
IKKα antibody, and immunoblotted with the indicated antibodies. (b,c,e) BMDMs from WT 
mice were pre-treated with either DMSO or 10 nM or 100 nM okadaic acid for 15 minutes. 
Cells were then left untreated or treated with LPS (1 μg/ml) for 4 hours, or LPS (1 μg/ml) 4 
hours + 5 mM ATP (30 min) (b, c) or 10 uM nigericin (30 min) (e). Cell lysates and 
supernatants were collected together and were immunoblotted with the indicated antibodies 
(b,e), and cell-free supernatants were collected and IL-1β and TNF-α levels were assessed 
by ELISA (c). (f,g) WT BMDMs were infected with lentivirus containing either control or 
anti-PP2A-C shRNA. Cells were either left untreated or treated with LPS (1 μg/ml) for 4 
hours, followed by 5 mM ATP for 30 min when indicated (f), or were transfected with 
poly(dA:dT) (1.5 μg/ml) using lipofectamine 2000 for 4 hours (g). After the indicated time, 
cell lysates and supernatants were collected together and immunoblotted with indicated 
antibodies. N.D. indicates not detectable, and “UN” indicates left untreated. Data are 
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representative of at least four independent experiments. Error bars represent s.e.m. of 
technical replicates. * P <0.05 by Mann-Whitney test.
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Figure 7. 
IKKi is required for ASC nuclear-to-cytosolic translocation and inflammasome activation 
(a) BMDMs from WT and IKKi−/− mice were treated with LPS (1 μg/ml) for 4 hours, 
followed by 30 min 5 mM ATP when indicated. Cell lysates and supernatants were then 
collected together and immunoblotted with the indicated antibodies. (b) Cell-free 
supernatants from (s) were analyzed by ELISA to determine levels of IL-1β (left panel) and 
TNF-α (right panel). (c) BMDMs from WT and IKKi−/− mice were transfected with 
poly(dA:dT) (1.5 μg/ml) using lipofectamine 2000 for 4 hours. Cell lysates and supernatants 
were then collected together and immunoblotted with the indicated antibodies. (d) BMDMs 
from WT and IKKi−/− mice were left untreated or treated with LPS (1 μg/ml) for 4 hours, 
LPS 4 hours + 5 mM ATP (30 min), or were transfected with poly(dA:dT) (1.5 μg/ml) using 
lipofectamine 2000 for 4 hours. Cells were then washed and fixed, and stained with anti-
ASC antibody and anti-IKKi antibody. Images were acquired using confocal microscopy 
with 60X magnification and 4X enlargement; scale bars are 5 μm (upper panels). LPS
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+ATP- and poly(dA:dT)-treated samples were quantified by counting the number of cells 
with ASC specks as a percentage of total cells counted in three fields. (lower panels) (e) 
BMDMs from WT and IKKi−/− mice were left untreated or treated with LPS (1 μg/ml) for 
15 minutes, 30 mins, 4 hours or LPS 15 mins and 4 hours + 5 mM ATP (30 min). Cells were 
then lysed and immunoprecipitated with anti-ASC antibody, followed by western blotting 
with indicated antibodies. N.D. indicates not detectable, and “UN” indicates left untreated. 
Data are representative of at least four independent experiments. Error bars represent s.e.m. 
of technical replicates. * P <0.05 by Mann-Whitney test.
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Figure 8. 
S58 of ASC is a critical residue for IKKi-mediated nuclear-to-cytosolic translocation and 
inflammasome activation (a) HEK 293 cells were transfected with FLAG-IKKi WT or 
FLAG-IKKi KD, along with either WT ASC or S58A ASC using lipofectamine 2000. 
Empty vector was used to normalize total plasmid transfected. Cells were then lysed, 
followed by immunoprecipitation with anti-ASC antibody, and in vitro kinase assay. (b,c) 
Immortalized ASC−/− macrophages were retrovirally reconstituted with WT ASC or S58A 
ASC, then either left untreated, treated with LPS (1 μg/ml) for 4 hours followed by 5 mM 
ATP (30 mins), or were transfected with poly(dA:dT) (1.5 μg/ml) for 4 hours using 
lipofectamine 2000. Cells were then washed and fixed, and stained with anti-ASC antibody 
and caspase-1 FLICA (FAM-YVAD-FMK), and images were acquired using confocal 
microscopy with 60X magnification and 4X enlargement; scale bars are 5 μm. Samples 
were quantified by counting the number of cells with ASC specks as a percentage of total 
cells counted in three fields (b). Or, lysates were immunoprecipitated with anti-ASC 
antibody and immunoblotted with the indicated antibodies (c). (d,e) Immortalized ASC−/− 
macrophages were retrovirally reconstituted with S193A ASC, S16A ASC, S193A/S58A 
ASC, or S16A/S58A ASC. Cells were treated with LPS (1 μg/ml) for 4 hours or with LPS (1 
μg/ml) for 4 hours followed by 5 mM ATP (30 mins). Lysates and supernatants were then 
collected together and immunoblotted with the indicated antibodies (d), or cells were 
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washed and fixed, stained with anti-ASC antibody and caspase-1 FLICA (FAM-YVAD-
FMK), and images were acquired using confocal microscopy with 60X magnification and 
4X enlargement; scale bars are 5 μm. Samples were quantified by counting the number of 
cells with ASC specks as a percentage of total cells counted in three fields (e). (f) WT ASC, 
S58A ASC, S193A/S58A ASC, and S16A/S58A ASC retrovirally reconstituted cells were 
transfected with poly(dA:dT) (1.5 μg/ml) using lipofectamine 2000 for 4 hours. Lysates and 
supernatants were then collected together and immunoblotted with the indicated antibodies. 
“UN” indicates left untreated. Data are representative of at least four independent 
experiments. Error bars represent s.e.m. of technical replicates. * P <0.05 by Mann-Whitney 
test.
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